A court in Louisiana granted the defendant’s motion to dismiss two of three product defect claims in a lawsuit.
Plaintiffs Stephanie and Robert Fuller accused the defendant, Eisai Inc. and Arena Pharmaceuticals Inc., of design defects, manufacturing defects, and safety misrepresentations related to its drug Belviq.
The weight loss drug is allegedly linked to breast cancer, according to the plaintiffs.
The court ruled that the Fullers did not provide sufficient evidence for their manufacturing defect claims, as well as their claims about breach of warranty.
The design defect claim is expected to continue to the Eastern District of Louisiana court.
Soure: Drug Watch
